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Abstract
Several innate and adaptive immune cell types participate in ischemia/reperfusion induced tissue injury. Amongst them,
platelets have received little attention as contributors in the process of tissue damage after ischemia reperfusion (I/R) injury.
It is currently unknown whether platelets participate through the immunologically important molecules including, CD40
and when activated, CD154 (CD40L), in the pathogenesis of I/R injury. We hypothesized that constitutive expression of CD40
and activation-induced expression of CD154 on platelets mediate local mesenteric and remote lung tissue damage after I/R
injury. Wild type (WT; C57BL/6J), CD40 and CD154 deficient mice underwent mesenteric ischemia for 30 minutes followed
by reperfusion for 3 hours. WT mice subjected to mesenteric I/R injury displayed both local intestinal and remote lung
damage. In contrast, there was significantly less intestinal damage and no remote lung injury in CD40 and CD154 deficient
mice when compared to WT mice. Platelet-depleted WT mice transfused with platelets from CD40 or CD154 deficient mice
failed to reconstitute remote lung damage. In contrast, when CD40 or CD154 deficient mice were transfused with WT
platelets lung tissue damage was re-established. Together, these findings suggest that multiple mechanisms are involved in
local and remote tissue injury and also identify platelet-expressed CD40 and/or CD154 as mediators of remote tissue
damage.
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Introduction
Tissue damage following ischemia reperfusion (I/R) occurs as a
consequence of deprivation of the blood flow followed by its return
to the affected tissue. Re-establishment of the blood supply initiates
an intense inflammatory response locally and subsequently in
remote organs that involve elements of both innate and adaptive
immune response [1]. Contributors to tissue damage after I/R
injury include several solubles such as natural Ig [2], complement
components [3], as well as cellular components including B [4], T
[5], NK, NKT cells [6], and neutrophils [7]. Inhibition of
complement or depletion of T or B cells has been used successfully
to prevent tissue damage after I/R injury [6]. However, the
contribution of platelets or platelet-derived factors in the
development of tissue damage after I/R injury has not been
thoroughly characterized.
Platelets typically express a pro-inflammatory phenotype and
have been shown to play an important role in the onset and
progression of chronic and acute inflammatory responses in
rheumatoid arthritis [8,9], systemic lupus erythematosus [10],
inflammatory bowel disease [11,12],vascular inflammation in graft
rejection [13] and more recently in ischemia reperfusion injury
[14]. Platelets have been also shown to activate the complement
pathway and that complement components may activate platelets
[15]. Thus, localized inflammation may be perpetuated in the
presence of both platelets and complement components.
Activation of platelets occurs predominantly through the
integrin, GPIIb3a (CD41–CD61), which is the major platelet
activation receptor. While binding of fibrinogen to GPIIb3a leads
to platelet activation [16], this activation may only be ‘‘transient’’
and may require additional integrins or cell surface receptors to act
in synergy culminating in terminal activation [17]. Once activated,
platelets express a pro-inflammatory phenotype whereby they
express and release cytokines, adhesion molecules, metallopro-
teases, and co-stimulatory molecules such as CD154 [17].
CD154 and CD40 are important immune co-stimulatory
molecules involved in isotype class switching in B cells, T cell
effector function [18], and monocyte/macrophage and endothelial
cell activation [19,20,21]. Platelets constitutively express CD40
and when activated, CD154. Engagement of platelet CD40 with
CD154 has been shown to induce the release of a-granules and
dense body contents; it also leads to transient cell surface
expression of CD154 prior to its release into circulation [17].
Together, CD154 and CD62P expression have been shown to
initiate platelet-platelet and platelet-leukocyte aggregation [22–
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platelets, monocytes, neutrophils and endothelial cells which may
culminate in remote tissue injury following mesenteric I/R. Here,
we test the hypothesis that platelet expression of CD40/CD154
mediates remote tissue injury after mesenteric I/R.
We demonstrate that both CD40 and CD154 expression on
platelets is important in remote lung tissue damage after
mesenteric I/R injury. Our study implicates CD40/CD154
expression on platelets as important mediators of remote tissue
damage.
Materials and Methods
Ethics Statement
All experiments were performed in accordance with the
guidelines and approval of the Institutional Animal Care and
Use Committee of the Beth Israel Deaconess Medical Center.
Mice
Adult, 8 week old male C57BL/6J, CD154
2/2 and CD40
2/2
mice were obtained from The Jackson Laboratory (Bar Harbor,
ME) and housed in the animal research facility at the Beth Israel
Deaconess Medical Center (BIDMC) prior to experimentation.
Eight to 12 week old male mice were used for all the experiments.
Both male and female mice up to 24–30 weeks old were used to
prepare purified platelets.
Ischemia Reperfusion Injury Protocol
Mice were prepared for surgery after 7 days of acclimatization.
They were randomly assigned to either sham or I/R groups.
Anesthesia was induced with 72 mg/kg pentobarbital (Nembutal,
Lundbeck Inc., Deerfield, IL) and maintained with 36 mg/kg of
pentobarbital by intraperitoneal injection.
Animals were subjected to I/R as previously described [25].
Briefly, a midline laparotomy was performed then the animals
were allowed a 30 minute equilibration period after which time
superior mesenteric artery was identified, isolated, and then
clamped for 30 minutes using a small non-traumatic micro
vascular clip. The clip was removed after this ischemic phase
and the intestines were allowed to reperfuse for up to 3 hours.
Sham-operated group were subjected to above-described surgical
intervention without artery occlusion. The laparotomy incision
was sutured, the mice resuscitated with 1.0 mL pre-warmed sterile
PBS subcutaneously and monitored during the reperfusion period.
Body temperature was maintained at 37uC throughout the
preparatory and experimental procedure. At the end of the
reperfusion period, mice were euthanized by carbon dioxide
asphyxiation and the tissues were harvested. A 20 cm long
segments [distal to the gastro duodenal junction] of small intestinal
specimens were removed, flushed with ice-cold PBS followed by
ice-cold 10%phosphate-buffered formalin prior to overnight
fixation in 10% phosphate-buffered formalin. Lung removal
consisted of intact extraction of the bronchial tree after expansion
with 200–300 mL of 10% phosphate-buffered formalin and fixed
overnight in 10% phosphate-buffered formalin.
Platelet Depletion
Two days prior to platelet transfusion and ischemia reperfusion,
mice received a single intraperitoneal injection of an affinity
purified endotoxin-free rabbit anti-mouse polyclonal antibody
prepared with commercially available rabbit anti-mouse platelet
anti-sera (Inter-Cell Technologies, Jupiter, FL) as described
previously [32].
Platelet Isolation and Transfusion
Whole blood was collected into syringes containing acid citrate
dextrose by cardiac transfusion into polypropylene tubes. The
blood mixture was centrifuged at room temperature and the upper
phase containing platelet rich plasma was isolated, the platelets
pelleted and resuspended in Tyrodes’ buffer for transfusion as
described previously [26]. Platelet numbers were determined using
Hemavet 850 (Drew Scientific, Farmington, CT) and were
adjusted to 26l0
9/mL. Platelet numbers were adjusted to
200 mL volumes and were transfused into platelet-depleted
recipient mice ten minutes prior to initiation of the experimental
midline laparotomy as described above.
Histology and Tissue injury scoring
Formalin-fixed intestine and lung tissues were extensively washed
in PBS, processed and embedded in paraffin for histological
analysis. The tissues embedded in paraffin were sectioned
transversely in 6 mm sections, and stained with hematoxylin and
eosin. The stained sections were then subjected to histological
scoring to evaluate the intestinal and lung tissue damage. All
histological analysis was performed in a blinded manner.
For each intestinal section, 100 villi were graded using a 6-tiered
scale as described previously [27]. Briefly, a normal appearing villus
was assigned a score of 0 while villi demonstrating tip distortion
were scored as 1. Villi without goblet cells and with Guggenheims’
spaces were scored as 2 and villi containing patchy disruption of the
epithelial cells were scored as 3. Villi demonstrating exposed, intact
lamina propria and sloughingofepithelial cellwere scoredas4. Villi
demonstrating exuding lamina propria were assigned a score of 5,
and lastly, villi with hemorrhage or denudation were scored as 6. In
case of lungs, alveolar and peri-luminal injury scores for each lung
section were calculated based on Cooke’s method [28]. Ten to
twenty fields at high power field magnification (4006) were viewed
for each lung section and scored for alveolar infiltration on a 3-
tiered scale. The following calculation for alveolar scores was
performed as follows: a score of 0 was given when no infiltrate was
present;a scoreof1 was givenwhentheinfiltrate could bevisualized
easily only at 4006; when infiltrates were readily visible, a score of 2
was assigned; and the score for consolidation was 3. Similarly, each
section was scored for peri-luminal damage (airway or blood vessel)
at 1006. The calculation for peri-luminal scores was as follows:
when there was no infiltrate a score of 0 was assigned; when the
infiltrate was between 1 and 3 cell layers thick, the score was 1; for
infiltrates ranging from 4 to 10 cells layers thick; a score of 2 was
assigned;and infiltrates .10cell layersthick werescoredas3.Based
on the overall involvement of the section, a severity score was
calculated: the severity score for 0–25% involvement was 1; a
severity score of 2 was assigned for 25–50% involvement; and the
severity score for .50% involvement was 3. For calculation of the
total lung injury score,the meansofalveolarandperi-luminal scores
for each section for summed up and multiplied by the severity score
which gave a final score ranging from 0 to 18.
Immunohistochemistry
For immunohistochemistry, formalin-fixed paraffin sections of
intestine and lung (6 mm thick) were subjected to rehydration and
antigenretrieval asrecommended bymanufacturer (BD Biosciences,
Billerica, MA). Samples were blocked in PBS+10% FCS for an hour
and the sections were incubated overnight with primary antibodies.
At the end of overnight incubation, the sections were washed
thoroughly and were incubated with secondary antibodies for 1 h.
Stained sections were developed with NovaRed (Vector Laborato-
ries, Burlingame, CA) and counterstained with hematoxylin (Vector
Laboratories, Burlingame, CA). Appropriate isotype controls were
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used: affinity-purified rabbit polyclonal antibody, rabbit anti-mouse
C3 (B-9,Santa Cruz Biotech, Santa Cruz, CA) and peroxidase-
conjugated affinity-purified secondary antibodies to rabbit immu-
noglobulin (Jackson ImmunoResearch, West Grove, PA)
Image Development
All images were viewed and captured using Nikon Eclipse 80i
microscope and adjusted using the adjustment feature in the RGB
channel using Adobe Photoshop CS2 (Adobe Systems, San Jose,
CA).
Statistical analysis
Data are presented as mean 6 SEM. All data were subjected to
statistical analysis using GraphPad Prism 4.0 for Windows
software program (GraphPad Software, San Diego, CA). Non-
parametric Mann-Whitney t test for unpaired samples was
performed to compare sham controls and experimental injury
data. A p#0.05 was considered significant.
Results
Intestinal and lung injury are reduced after mesenteric
ischemia/reperfusion in CD154
2/2 and CD40
2/2 mice
To establish the role of CD40 and its ligand CD154, in tissue
damage after mesenteric I/R, we first evaluated the levels of
intestinal and lung damage in wild type (WT), CD40
2/2 and
CD154
2/2 mice by histology (Figure 1). Mice lacking either CD40
or CD154 displayed a significant reduction in intestinal (Figure 1A–
Figure 1. Intestinal and lung injury is reduced after mesenteric ischemia/reperfusion in CD40
2/2 and CD154
2/2 mice. Hematoxylin and
eosin stained sections of mouse small intestine after 30 minutes of ischemia and 3 hours reperfusion. Images are representative of 3–4 mice per
group in two experiments. (A–F) Images of intestinal villi from sham and I/R. (G–L) Images of lung from sham and I/R, platelet-deficient sham and I/R.
All images shown are 2006magnification. (M, N) Injury score (mean 6 SD) in intestine and lung. *p#0.05, **p#0.01, and ***p#0.001 for I/R
compared to sham controls.
doi:10.1371/journal.pone.0032260.g001
Figure 2. Platelets numbers are not decreased in CD40
2/2 and
CD154
2/2 mice after mesenteric ischemia/reperfusion. CD40
2/2
and CD154
2/2 mice were bled before and after mesenteric I/R via
cardiac puncture. Platelet numbers were determined using Hemavet
850 (Drew Scientific, Farmington, CT).
doi:10.1371/journal.pone.0032260.g002
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mesenteric I/R. Cumulative data are shown in Figure 1M and
Figure 1N.
Role of CD40
2/2 and CD154
2/2 platelets in local and
remote tissue injury after mesenteric ischemia
reperfusion injury
We asked whether deficiency of CD40 and CD154 affects the
numbers of circulating platelets. As it can be seen in Figure 2 the
absence of CD40 and CD154 did not alter the numbers of
circulating platelets before and after IR. Importantly, CD40 and
CD154 deficient animals have the same numbers of circulating
platelets compared to WT B6 mice [14].
To further evaluate the role of platelet-expressed CD40 and
CD154 in local ischemia reperfusion, B6 mice were treated with
an anti-platelet depleting antibody and subsequently transfused
with platelets isolated either from CD40
2/2 or CD154
2/2 mice.
Intestinal damage was evaluated by histology. Representative
experiments are shown in Figure 3A–F and cumulative data are
shown in Figure 3G. Although transfusion of CD40 or CD154
Figure 3. Transfusion of either CD40
2/2 and CD154
2/2 platelets protects platelet depleted B6 mice from remote lung injury but not
from local intestinal injury. (A–L) Hematoxylin and eosin stained sections of mouse small intestine and lung from B6 and platelet depleted B6
mice transfused with either CD40
2/2 or CD154
2/2 platelets after 30 minutes of ischemia and 3 hours reperfusion. Images are representative of 3–4
mice per group in two experiments. All images shown are 2006magnification. (M)Intestinal injury score and (N) Lung injury score (mean 6 SD). ns:
not significant *p#0.05, **p#0.01, and ***p#0.001 for I/R compared to sham controls.
doi:10.1371/journal.pone.0032260.g003
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intestinal tissue damage it did not reach statistical significance
compared with control B6 mice. In contrast remote lung damage
was significantly reduced in the transfused B6 mice that received
platelets from CD402/2 and CD1542/2. Representative
experiments are shown in Figure 3G–L and cumulative data are
shown in Figure 3H. The data indicates that platelets, and
especially platelet-expressed CD40 and CD154, molecules are
important for remote damage after mesenteric I/R.
To further evaluate the role of platelet-expressed CD40 and
CD154, platelet-transfused intestinal and lung tissues were stained
for platelets and complement (Figure 4). Reduced number of
platelets were observed in the lungs of mice that were first depleted
of platelets and subsequently transfused with CD40 or CD154
deficient platelets (Figure 4A–I). C3 deposition followed a pattern
similar to that observed with platelets (Figure 4J–R). These
experiments indicate that activated platelets may drive comple-
ment pathway activation leading to remote tissue damage after
mesenteric I/R.
Local and remote injury is re-established in CD40
2/2 and
CD154
2/2 mice transfused with B6 platelets
To confirm the role of platelet-expressed CD40 and CD154
molecules in remote lung injury, we transfused platelets from B6
mice back to platelet-depleted CD40
2/2 and CD154
2/2 mice and
performed mesenteric I/R. As expected, lung injury was re-
established in these mice (Representative data Figure 5A–D,
cumulative data, Figure 5M). Furthermore, staining for platelets
and C3 showed an increase in platelet sequestration (Figure 5E–H)
and C3 deposition (Figure 5I–L) in the lung after mesenteric I/R.
Together, these findings suggest that platelet-expressed CD40 and
CD154 orchestrate lung damage by controlling the trafficking of
platelets to the lung.
Discussion
Experiments reported in this article grant platelet-expressed
CD40/CD154 an important role in the expression of mesenteric
I/R mediated remote lung injury. We first show a reduced
intestinal and no lung injury in CD402/2 and CD1542/2 mice
after mesenteric I/R compared to WT controls. Our experiments
demonstrate that transfusion of platelets from either CD402/2 or
CD1542/2 mice to platelet depleted B6 mice resulted in less or
no lung damage compared to the control mice. In contrast, the
lung tissue damage was re-established when WT platelets were
transfused to platelet-depleted CD402/2 and CD1542/2 mice.
Platelets contribute significantly to the expression of tissue damage
in several conditions because of their pro-inflammatory nature
[18,29–32]. Recently, platelets have been demonstrated to contribute
tothepathogenesisofanumberofinflammatorydiseases.Specifically,
it has been demonstrated that platelets after activation by circulating
immune complexes, can form aggregates with monocytes and
dendritic cells and contribute to the severity of the disease in patients
with systemic lupus erythematosus patients [10]. In a mouse model of
rheumatoid arthritis platelets were shown to play a central role in the
control of leukocyte-endothelial interactions through P-selectin and
contributing to the joint damage observed in these mice [8,33].
Moreover, increased levels of activated platelets and platelet-derived
factors have also been found in patients with inflammatory bowel
disease [12,34–36] and with ischemic stroke [37–40].
CD40 is a member of the tumor necrosis factor (TNF) receptor
superfamily, and is constitutively expressed on the surface of resting
and activated platelets and vascular endothelial cells. Its ligand
CD154, is present inside in alpha granules in resting platelets and
when platelets are activated CD154 translocates to the membrane
for up to 90 minutes prior to its being where it is cleaved by matrix
metalloproteases and released in a soluble form. Platelets are the
Figure 4. Reduced platelet and complement deposition in lungs after ischemia/reperfusion in CD40
2/2 and CD154
2/2 platelet
transfused B6 mice. (A–R) Tissue sections of lung from B6 (top row) and platelet depleted B6 mice transfused with either CD154
2/2 (bottom row)
or CD40
2/2 (middle row) platelets and mice after 30 minutes of mesenteric ischemia 3 hrs of reperfusion and sham controls were stained for platelets
(A–I) or C3 complement factor (J–R) and counterstained with hematoxylin (blue). Images are representative of 3–4 mice per group. Large arrows:
indicate areas with increased intensity of staining. Small arrows: indicate areas with reduced intensity of staining.
doi:10.1371/journal.pone.0032260.g004
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recent studies have demonstrated a direct link between CD40/
CD154 and complement. Specifically, C4-bining protein, an
inhibitor of C3 convertase is able to interfere with the CD40/
CD154 interactions by creating complexes with the CD154 and
thusinhibitingthedownstreamsignalingpathways[42].Theroleof
the CD40 and CD154 pathway has been extensively investigated in
many diseases including cardiovascular diseases [29,43,44]. How-
ever, the role for platelet CD40/CD154 has not yet been evaluated
in mesenteric ischemia reperfusion injury.
Mice deficient in CD40 or CD154 have altered serum
immunoglobulin profile with decreased levels of IgG but increased
levels of IgM [45]. In our experiments, CD402/2 and CD1542/2
mice also showeddecreased levels of IgG1, IgG2a, IgG2b, IgG3 but
normal IgA and IgM levels (data not shown). Because natural
antibodies have been implicated in the instigation of IR injury
[2,46] we considered that the decreased local and remote lung
injury that we observed in CD402/2 and CD1542/2 mice could
be due to decreased levels of naturally occurring Ig initiating I/R
injury. To test this hypothesis, we injected normal IgG into
CD154KO mice prior to IR and this failed to reestablish organ
damage following IR (data not shown). This information further
strengthens our conclusion that it is the absence of CD40 and
CD154 in platelets that accounts for the decreased IR injury in
CD402/2 and CD1542/2 mice.
In conclusion we have demonstrated that the expression of
CD40 and/or CD154 on platelets is necessary for the expression
of remote organ damage after mesenteric I/R injury. Based on
these findings we suggest that the use of available compounds
against platelet activation or blocking CD40–CD154 interaction
may represent an effective adjuvant therapy in efforts to inhibit or
even prevent the remote tissue damage.
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Figure 5. Remote lung injury is re-established in CD154
2/2 and CD40
2/2 mice transfused with B6 platelets. (A–D) Hematoxylin and eosin,
(E–H) platelets and (I–L) C3 complement factor stained sections of mouse lung from CD154
2/2 and CD40
2/2 mice transfused with B6 platelets after
30 minutes of ischemia and 3 hours reperfusion. Images are representative of 3–4 mice per group in two experiments. All images shown are
2006magnification. (M)Injury score (mean 6 SD) in intestine and lung. ns: not significant *p#0.05, **p#0.01, and ***p#0.001 for I/R compared to
sham controls. Small arrows: indicate areas of positive staining.
doi:10.1371/journal.pone.0032260.g005
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